Treatment of schizophrenia negative symptoms: future prospects (Q36402997)

14 August 2017

1 reference

title

Treatment of schizophrenia negative symptoms: future prospects (English)

1 reference

14 August 2017

0 references

Stephen M Erhart

1

1 reference

14 August 2017

Stephen R Marder

series ordinal

2

1 reference

14 August 2017

William T Carpenter

series ordinal

3

1 reference

14 August 2017

language of work or name

English

0 references

publication date

21 February 2006

1 reference

14 August 2017

Schizophrenia Bulletin

1 reference

14 August 2017

32

1 reference

14 August 2017

2

1 reference

14 August 2017

234-237

1 reference

Management of the negative symptoms of schizophrenia: new treatment options

14 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2632230

Maximizing the synergy between pharmacotherapy and psychosocial therapies for schizophrenia

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2632230

Odor identification, eye tracking and deficit syndrome schizophrenia.

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2632230

Efficacy and extrapyramidal side-effects of the new antipsychotics olanzapine, quetiapine, risperidone, and sertindole compared to conventional antipsychotics and placebo. A meta-analysis of randomized controlled trials

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2632230

Revisiting the factor structure for positive and negative symptoms: evidence from a large heterogeneous group of psychiatric patients

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2632230

Population and familial association between the D4 dopamine receptor gene and measures of Novelty Seeking

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2632230

New drugs for the treatment of schizophrenic patients

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2632230

Negative symptoms in schizophrenia. Definition and reliability

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2632230

A systematic method for clinical description and classification of personality variants. A proposal

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2632230

Positive and negative symptom response to clozapine in schizophrenic patients with and without the deficit syndrome.

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2632230

Characterization of psychotic conditions. Use of the domains of psychopathology model.

28 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2632230

The association between the dopamine D4 receptor (D4DR) 16 amino acid repeat polymorphism and novelty seeking.

28 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2632230

Olanzapine versus haloperidol in the treatment of schizophrenia and schizoaffective and schizophreniform disorders: results of an international collaborative trial

28 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2632230

Comparison of efficacy of social skills training for deficit and nondeficit negative symptoms in schizophrenia

28 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2632230

Double-blind, placebo-controlled, crossover trial of glycine adjuvant therapy for treatment-resistant schizophrenia.

28 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2632230

The Schedule for the Deficit syndrome: an instrument for research in schizophrenia.

28 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2632230

Comparative effects of glycine and D-cycloserine on persistent negative symptoms in schizophrenia: a retrospective analysis

28 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2632230

Effects of rivastigmine on cognitive function and quality of life in patients with schizophrenia

21 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2632230

Components of the smooth pursuit function in deficit and nondeficit schizophrenia

21 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2632230

Adjuvant galantamine administration improves negative symptoms in a patient with treatment-refractory schizophrenia

21 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2632230

Clinical profile of an atypical antipsychotic: risperidone

21 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2632230

Donepezil in schizophrenia--is it helpful? An experimental design case study

21 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2632230

Oxytocin and vasopressin as candidate genes for psychiatric disorders: lessons from animal models.

21 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2632230

Association between serotonin transporter gene polymorphism and anxiety-related traits.

21 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2632230

Factor structure of the negative symptom assessment.

21 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2632230

Positive and negative symptoms and and adjustment in severely mentally ill outpatients

21 September 2018

1 reference

12 December 2020

Bipolar II with and without cyclothymic temperament: "dark" and "sunny" expressions of soft bipolarity

1 reference

12 December 2020

Empirical assessment of the factorial structure of clinical symptoms in schizophrenia: negative symptoms

1 reference

12 December 2020

Negative symptoms in schizophrenia: a confirmatory factor analysis of competing models

1 reference

12 December 2020

A placebo-controlled crossover trial of D-cycloserine added to clozapine in patients with schizophrenia

1 reference

12 December 2020

Identifiers

DOI

10.1093/SCHBUL/SBJ055

1 reference

14 August 2017

1 reference

14 August 2017

1 reference